These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34405637)

  • 1. [Efficacy and safety of infliximab in the treatment of pediatirc Crohn's disease].
    Xu X; Xiao Y; Yu Y; Li J; Huang YQ; Cao W; Hu H; Zhang T; Xu CD; Wang XQ
    Zhonghua Er Ke Za Zhi; 2021 Jul; 59(7):557-562. PubMed ID: 34405637
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy of infliximab in treatment of pediatric Crohn's disease in China].
    Luo Y; Yu J; Zhao H; Peng K; Lou J; Ma M; Chen J
    Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):688-92. PubMed ID: 25476432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
    Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease.
    Marshanski T; Fanous E; Tal N; Perets TT; Matar M; Weintraub Y; Shamir R; Shouval DS
    J Pediatr Gastroenterol Nutr; 2024 Sep; 79(3):564-572. PubMed ID: 38979682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
    Colman RJ; Vuijk SA; Mathôt RAA; Van Limbergen J; Jongsma MME; Schreurs MWJ; Minar P; de Ridder L; D'Haens GRAM
    Inflamm Bowel Dis; 2024 Oct; 30(10):1678-1685. PubMed ID: 38167922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Motoya S; Kinjo F; Maemoto A; Matsumoto T; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    PLoS One; 2018; 13(8):e0201956. PubMed ID: 30114224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
    Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
    Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of combination therapy with infliximab for Crohn's disease: a systematic review and network meta-analysis.
    Han B; Tang D; Lv X; Li S; Fan J; Xu X; Zhang J; Xu S; Ye W; Huang Z; Zhan L; Lv X
    Int J Colorectal Dis; 2023 Mar; 38(1):82. PubMed ID: 36971914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease].
    Deng X; Yu Y; Wang XQ; Li J; Xu X; Xu CD; Xiao Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1246-1251. PubMed ID: 36398551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
    Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
    Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China.
    Zhang T; Wang Z; Fan R; Zhang M; Lin Y; Hong L; Zhou X; Hu S; Cheng M; Zhong J
    Biomed Res Int; 2016; 2016():8648307. PubMed ID: 27896276
    [No Abstract]   [Full Text] [Related]  

  • 16. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
    Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn's disease patients in western China.
    Song X; Zhang H; Song J; Wang H; Guo H; Zhou X
    Clin Exp Med; 2024 Oct; 24(1):237. PubMed ID: 39365401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
    J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.